Elizabeth Holmes convinced some of the world’s most powerful investors that she could revolutionize healthcare with a single drop of blood.

She raised hundreds of millions of dollars, built a company valued at $9 billion, landed magazine covers, and became one of Silicon Valley’s most celebrated founders.

There was just one problem. The technology didn’t work as promised.

Now, three years after entering prison, Holmes is back in the spotlight.

Her new documentary, You Can See Everything , opened in theaters on October 16, and it’s raising some uncomfortable questions about the startup world, the power of storytelling, and what happens when founders become more invested in their vision than the reality of their business.

The $9 Billion Startup That Couldn’t Deliver

For anyone who missed the Theranos scandal, here’s the short version.

Holmes dropped out of Stanford at 19 to build a company that promised to run extensive medical tests using just a tiny amount of blood.

It was a compelling idea. Blood testing was expensive, inconvenient, and often required needles and multiple vials. Holmes promised to change that.

Investors loved it. So did the media.

At its peak, Theranos was valued at approximately $9 billion. According to the Securities and Exchange Commission , the company raised more than $700 million from investors while making false or exaggerated claims about its technology and financial performance.

A 2015 Wall Street Journal investigation helped expose the problems. Theranos eventually collapsed, and Holmes was convicted in 2022 of conspiracy and wire fraud involving investors. She received an 11-year-and-three-month prison sentence .

But the new documentary suggests that Holmes hasn’t abandoned the story she told about herself.

What The New Documentary Reveals

Directed by Nathan Fielder and Lance Oppenheim, the nearly three-hour film began with extraordinary access to Holmes during her final 34 days before prison.

According to coverage of the documentary in The Wall Street Journal , Holmes continues to maintain her innocence and defend her original vision. Her partner, Billy Evans, also discusses efforts to revive that vision through another healthcare venture.

At one point, actress Amanda Seyfried, who portrayed Holmes in The Dropout , enters the documentary to recreate moments the filmmakers couldn’t capture.

The result blurs the line between performance and reality, raising a question explored in The Washington Post’s review that extends well beyond Holmes: How much of what we believe about successful founders comes from measurable results, and how much comes from the stories they tell?

Three Questions Every Founder Should Be Asking

1. When does selling a vision become selling something that doesn’t exist?

Every startup begins with something unproven.

Founders pitch products they haven’t finished, markets they haven’t captured, and revenue they haven’t earned.

That’s normal. Investors understand they’re taking risks.

But there’s a difference between saying you’re building technology that might change an industry and claiming you’ve already achieved something you haven’t.

Theranos crossed that line.

The distinction matters especially today, when AI startups are competing to make increasingly ambitious claims about what their technology can do.

2. Are people validating your business or just validating your story?

Holmes attracted influential investors and prominent board members, including former U.S. secretaries of state Henry Kissinger and George Shultz.

Their involvement helped give Theranos credibility.

Yet impressive names weren’t evidence that its blood-testing technology worked.

For founders, it’s an important distinction. A successful fundraising round, a famous investor, or a viral announcement can create momentum without proving the underlying business model.

Attention can open doors. It can’t substitute for a working product.

3. What happens when your identity becomes your company?

Perhaps the documentary’s most interesting theme is Holmes’ continued attachment to her original vision.

Even after Theranos collapsed and she was convicted, she continues defending the technology and her intentions, something also examined in the Associated Press’ review of the film .

There’s a psychological dimension here worth understanding.

Researchers studying entrepreneurial escalation of commitment have examined why founders continue investing in struggling ventures despite mounting evidence against them.

When years of work, personal reputation, and identity are tied to a business, changing direction can become increasingly difficult.

That’s why the ability to separate yourself from your idea matters.

A failed experiment doesn’t have to mean a failed founder. But refusing to acknowledge a failed experiment can create much bigger problems.

Why The Theranos Story Still Matters

The timing of You Can See Everything is interesting.

We’re entering another era of enormous technological promises, with AI founders raising billions and racing to establish themselves as the next generation of industry-changing companies.

Many will build extraordinary businesses.

Others will discover their technology isn’t ready, their market isn’t there, or their original assumptions were wrong.

The Theranos scandal isn’t evidence that ambitious founders should stop making ambitious promises.

It’s evidence that those promises need to remain connected to reality.

Because building something revolutionary requires convincing people to believe in what doesn’t exist yet.

The challenge is knowing when to stop selling the vision and start confronting the evidence.